Misleading results of screening for illicit drugs during efavirenz treatment [5]

AIDS

Volumn 21, Issue 10, 2007, Pages 1390-1391

  Röder, Claudia Stephanie ^a   Heinrich, Tilman ^a   Gehrig, Anne Kathrin ^a   Mikus, Gerd ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; EFAVIRENZ; MIDAZOLAM; TETRAHYDROCANNABINOL;

CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SCREENING; DRUG URINE LEVEL; FALSE POSITIVE RESULT; HUMAN; HUMAN EXPERIMENT; IMMUNOCHEMISTRY; LETTER; NORMAL HUMAN; PRIORITY JOURNAL; TREATMENT DURATION; URINALYSIS;

BENZODIAZEPINES; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOASSAY; MIDAZOLAM; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE ABUSE DETECTION; TETRAHYDROCANNABINOL;

EID: 34249987898     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32814e6b3e     Document Type: Letter

References (4)

1. Product information Sustiva. Bristol-Myers Squibb Company, Princeton, USA; 2006.
2. Sinicco A, Raiteri R, Rossati A, Savarino A, Di Perri G. Efavirenz interference in estradiol ELISA assay [Letter]. Clin Chem 2000; 46:734-735.
3. Rossi S, Yaksh T, Bentley H, van den BG, Grant I, Ellis R. Characterization of interference with 6 commercial delta9- tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine [Letter]. Clin Chem 2006; 52:896-897.
4. Package insert, Triage 8. Biosite, San Diego, USA; 2007.